We offer an extensive panel of inflammatory bowel disease models in mice and rats, including genetically modified, chemically induced, and adoptive transfer-related IBD models. Let our experts help you choose the best IBD animal models to advance your research programs. Learn more about our platform of inflammation models  

Drug Discovery Chemistry Conference 2023 WuXi AppTec has developed technologies to facilitate RNA small molecule screening, an exciting frontier in drug discovery. SHAPE-MaP is applied to determine RNA structure and dynamics and verify small molecule binding. We utilize the “DNA-Zipper” strategy to enable DNA-encoded libraries to identify RNA binders. With other technologies including fragment-based drug …Read More >

Drug Discovery Chemistry Conference 2023 Powerful biophysical and structural biology tools enable the study of large numbers of covalent fragments and are opening up new possibilities in the treatment of various diseases. Here, Dr. Moran Jerabek-Willemsen, Head of Biophysics & Screening in WuXi Biology reports the results of a covalent FBDD project on Bruton’s Tyrosine …Read More >

Drug Discovery Chemistry Conference 2023 DNA-Encoded library (DEL) screening is now commonly used in the pharmaceutical industry to find novel chemical matter that modulates protein targets of interest.  Point-by-point, Dr. Alex Satz, Executive Director, WuXi Biology will discuss the primary challenges and limitations of DEL screening, and concisely state the current abilities of the technology …Read More >

Our comprehensive panel of orthotopic and metastasis syngeneic models includes: 17 orthotopic/disseminated models covering 10 cancer types; Organ-based orthotopic models of solid tumor cell lines; IV injection disseminated models of hematopoietic cancer cell lines; 13 experimental metastasis models covering 7 cancer types

DLL3 related lung cancer PDX models, validated by RNA-Seq and IHC staining

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification or gene mutation can promote the development of multiple cancer types, including gastric, liver, lung, breast, pancreatic cancer, and glioblastoma (through the stimulation of multiple signaling pathways).  As a result, c-Met is considered a clinically …Read More >

Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types: 18 CDX models carrying BRAF mutation (V600E, G469A, G464V, G466V, G596R or N581Y), covering melanoma, breast cancer, lung cancer and colorectal cancer 18 PDX models carrying BRAF mutation (V600E, G469A, G469E, D594N or N581S), covering melanoma, pancreatic cancer, …Read More >

Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared with mice include: more similar metabolism and physiology to human; easier use for orthotopic model surgery, vascular manipulation, and imaging; larger sampling sizes to ensure sufficient amount for bioanalysis; consistent animal species to toxicology studies …Read More >